Philidor
Former Valeant executive and Philidor CEO charged with fraud
November 18, 2016Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud
Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …
Valeant under criminal investigation
August 11, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, investigation
Valeant Pharmaceuticals International is currently under investigation by the US attorney’s office in Manhattan over suspicions that the firm intentionally …
Valeant’s ad hoc committee closes chapter on Philidor controversy
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee
Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
Valeant ends controversial litigation with R&O Pharmacy
March 10, 2016Litigation, Philidor, Valeant, controversy, r&o pharmacy, scandal
Valeant has announced that, in conjunction with R&O Pharmacy, its has jointly requested that the Court dismiss the litigation between …
Former Deputy Attorney General called in to advise Valeant after fraud allegations
November 2, 2015Medical Communications, Sales and Marketing Mark Filip, Philidor, Valeant, fraud
Valeant Pharmaceuticals’ board of directors has appointed former Deputy Attorney General of the United States Mark Filip to advise the …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
